Astrazeneca (AZN) Cash from Financing Activities (2009 - 2026)

Astrazeneca's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$2.6 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 600.39% year-over-year to -$2.6 billion; the TTM figure through Jun 2026 stood at -$7.7 billion (up 25.55% YoY), while the FY2025 annual figure was -$7.5 billion, down 88.79% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at -$2.6 billion, down from $267.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $2.0 billion in Q1 2024, with the low at -$6.6 billion in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$2.3 billion (2025), against an average of -$2.4 billion.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities soared 199.85% in 2024, then slumped 600.39% in 2026.
• Astrazeneca's Cash from Financing Activities stood at -$6.5 billion in 2022, then fell by 1.58% to -$6.6 billion in 2023, then soared by 39.15% to -$4.0 billion in 2024, then rose by 17.87% to -$3.3 billion in 2025, then climbed by 21.02% to -$2.6 billion in 2026.
• Business Quant data shows AZN's Cash from Financing Activities at -$2.6 billion in Q2 2026, $267.0 million in Q1 2026, and -$3.3 billion in Q4 2025.